(Q37788210)

23 August 2017

title

Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection (English)

1 reference

23 August 2017

0 references

1 reference

1 reference

1 reference

2

Caroline M Perry

1 reference

23 August 2017

Jamie D Croxtall

1

1 reference

23 August 2017

publication date

1 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

70

1 reference

23 August 2017

issue

14

1 reference

23 August 2017

page(s)

1885-1915

1 reference

A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.

23 August 2017

cites work

1 reference

12 December 2020

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

1 reference

12 December 2020

Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults

1 reference

12 December 2020

Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy

1 reference

12 December 2020

Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.

1 reference

12 December 2020

A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks

1 reference

12 December 2020

Long-term antiretroviral efficacy and safety of lopinavir/ritonavir in HAART-experienced subjects: 4 year follow-up study

1 reference

12 December 2020

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine

1 reference

12 December 2020

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children

1 reference

12 December 2020

Reduced lopinavir exposure during pregnancy

1 reference

12 December 2020

Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks

1 reference

12 December 2020

Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.

1 reference

12 December 2020

Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.

1 reference

12 December 2020

A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen

1 reference

12 December 2020

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

1 reference

12 December 2020

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures

1 reference

12 December 2020

Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.

1 reference

12 December 2020

Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients

1 reference

12 December 2020

A review of low-dose ritonavir in protease inhibitor combination therapy

1 reference

12 December 2020

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

1 reference

12 December 2020

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis

1 reference

12 December 2020

Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction

1 reference

12 December 2020

The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients

1 reference

12 December 2020

Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment

1 reference

12 December 2020

Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.

1 reference

12 December 2020

Lopinavir/ritonavir: a review of its use in the management of HIV infection

1 reference

12 December 2020

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

1 reference

12 December 2020

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

12 December 2020

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

1 reference

12 December 2020

Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates

1 reference

12 December 2020

Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.

1 reference

12 December 2020

Limited Penetration of Lopinavir and Ritonavir in the Genital Tract of Men Infected with HIV-1 in Brazil

1 reference

12 December 2020

Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans

1 reference

12 December 2020

Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients

1 reference

12 December 2020

Class-sparing regimens for initial treatment of HIV-1 infection

1 reference

12 December 2020

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.

1 reference

12 December 2020

Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children.

1 reference

12 December 2020

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

1 reference

12 December 2020

1 reference

12 December 2020

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

1 reference

12 December 2020

Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain

1 reference

12 December 2020

Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience

1 reference

12 December 2020

Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen

1 reference

12 December 2020

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial

1 reference

12 December 2020

Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.

1 reference

12 December 2020

Atazanavir: a review of its use in the management of HIV-1 infection.

1 reference

12 December 2020

Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV.

1 reference

12 December 2020

Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial

1 reference

12 December 2020

Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients

1 reference

12 December 2020

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

1 reference

12 December 2020

Atazanavir: a review of its use in the management of HIV infection

1 reference

12 December 2020

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

1 reference

12 December 2020

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

1 reference

12 December 2020

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

1 reference

12 December 2020

Study of the gastrointestinal tolerance of a new tablet formulation of the lopinavir/ritonavir antiretroviral in HIV-infected patients

1 reference

12 December 2020

ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease

1 reference

12 December 2020

A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks

1 reference

12 December 2020

Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation

1 reference

12 December 2020

Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.

1 reference

12 December 2020

Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance

1 reference

12 December 2020

Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients

1 reference

12 December 2020

Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study

1 reference

12 December 2020

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st

1 reference

12 December 2020

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study

1 reference

12 December 2020

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

1 reference

12 December 2020

A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.

1 reference

12 December 2020

Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.

1 reference

12 December 2020

The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.

1 reference

12 December 2020

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

1 reference

12 December 2020

Lopinavir/ritonavir: a review of its use in the management of HIV infection

1 reference

12 December 2020

Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial

1 reference

12 December 2020

High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response

1 reference

12 December 2020

In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification

1 reference

12 December 2020

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

1 reference

12 December 2020

Limited penetration of lopinavir into seminal plasma of HIV-1-infected men.

1 reference

12 December 2020

Translating efficacy into effectiveness in antiretroviral therapy: beyond the pill count

1 reference

12 December 2020

Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores

1 reference

12 December 2020

10.2165/11204950-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

23 August 2017

1014927572

0 references

1 reference